


SK Bioscience evaluates partnership with Gates Foundation for next-gen preventive medicines

22 August 2025 | News

Aims to advance global public health and expand equitable access to vaccines worldwide



SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that it held an exclusive meeting with the Gates Foundation as part of Bill Gates' visit to Korea to discuss ways to enhance global health collaborations.

On August 20, Trevor Mundel, President of Global Health of the Gates Foundation, and other key foundation representatives attended a meeting in Yeouido, Seoul, along with Andrew Chey, Vice-Chairman of SK discovery, and Jaeyong Ahn, CEO of SK bioscience.

Both organizations reaffirmed their commitment to working together on vaccine development and global public health projects during the meeting. A discussion was also held regarding the expansion of cooperation in next-generation preventive medicines, with an emphasis on the development of pandemic-preparedness medicines.

The Gates Foundation and SK bioscience have collaborated on multiple projects since 2013, including typhoid vaccines and pediatric diarrhea vaccines, contributing to global public health. A significant milestone in their collaboration was the successful development and commercialization of SKYCovione in 2022, Korea's first domestically developed COVID-19 vaccine. A celebration of the achievement was held in Korea that year by Bill Gates and Trevor Mundel, who met with Tony

Chey, Chairman of SK Group, and Andrew Chey, Vice-Chairman of SK Discovery.

To advance public health and expand equitable access to vaccines worldwide, SK bioscience is committed to working with global partners.

Image Caption: From the third left: Trevor Mundel, President of Global Health, Gates Foundation, Andrew Chey, Vice-Chairman of SK discovery, Jaeyong Ahn, CEO of SK bioscience